Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
In children with chronic kidney disease, progression to end-stage renal failure is associated
with high patient morbidity and poor quality of life. In adults, inhibition of the renin
angiotensin system (RAS) slows down the rate of renal failure progression. This concept is as
yet unproven in children, in whom chronic renal failure (CRF) is more commonly due to
hypo/dysplastic malformations than to acquired glomerulopathies as typical for adult chronic
kidney disease. The current project aims at assessing the genetic and molecular mechanisms
and cardiovascular consequences of progressive CRF and to develop a strategy of
pharmacological renoprotection in children.
Phase:
Phase 3
Details
Lead Sponsor:
Heidelberg University
Collaborators:
Aventis Pharmaceuticals Baxter Healthcare Corporation Boehringer Ingelheim European Commission